Skip to main content
Fig. 7 | Malaria Journal

Fig. 7

From: Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas

Fig. 7

Prevalence of individuals presenting IgG1, IgG2, IgG3 and IgG4 antibodies that recognizes GMZ2.6c. 1P < 0.0001, CZS IgG1 versus CZS IgG2 and IgG4; 2P = 0.01, ML IgG1 versus ML IgG2; P < 0.001, ML IgG1 versus ML IgG4; 3P < 0.0001, GJ IgG1 versus GJ IgG2 and IgG4; 4P < 0.0001, CZS IgG3 versus CZS IgG2 and IgG4; 5P = 0.01, ML IgG3 versus ML IgG2; P < 0.0001ML IgG3 versus ML IgG4; 6P < 0.0001; GJ IgG3 versus GJ IgG2 and IgG4. Prevalence of responders were compared by Chi-squared tests

Back to article page